We are contrasting Celsion Corporation (NASDAQ:CLSN) and its competitors on their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation. They are Biotechnology companies, competing one another.
Insider and Institutional Ownership
9.2% of Celsion Corporation’s shares are owned by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are owned by institutional investors. On other hand Celsion Corporation has 0.4% of its shares owned by company insiders versus an average of 8.45% insiders ownership for its peers.
Profitability
Table 1 has Celsion Corporation and its peers’ return on equity, return on assets and net margins.
| Net Margins | Return on Equity | Return on Assets | |
| Celsion Corporation | 1,507,406,913.12% | -51.10% | -21.40% |
| Industry Average | 812.10% | 105.95% | 28.39% |
Earnings and Valuation
The following data compares Celsion Corporation and its peers’ valuation, top-line revenue and net profit.
| Net Income | Gross Revenue | Price/Earnings Ratio | |
| Celsion Corporation | 22.59M | 2 | 0.00 |
| Industry Average | 33.76M | 4.16M | 35.97 |
Analyst Ratings
Table 3 shows breakdown of current ratings for Celsion Corporation and its peers.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Celsion Corporation | 0 | 0 | 1 | 3.00 |
| Industry Average | 1.10 | 1.78 | 2.38 | 2.81 |
Celsion Corporation currently has an average price target of $8, suggesting a potential upside of 447.95%. As a group, Biotechnology companies have a potential upside of 168.19%. Based on the results given earlier the equities research analysts’ view is that Celsion Corporation’s peers are looking more favorable than the stock itself.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Celsion Corporation and its competitors.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Celsion Corporation | -1.13% | -0.57% | -20.45% | -18.22% | -35.19% | 24.11% |
| Industry Average | 5.82% | 9.20% | 28.08% | 41.63% | 73.35% | 54.83% |
For the past year Celsion Corporation’s stock price has smaller growth than the average for its peers.
Liquidity
The Current Ratio and a Quick Ratio of Celsion Corporation are 4.2 and 4.2. Competitively, Celsion Corporation’s competitors have 7.07 and 6.86 for Current and Quick Ratio. Celsion Corporation’s rivals have better ability to pay short and long-term obligations than Celsion Corporation.
Risk & Volatility
Celsion Corporation is 95.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 1.95. In other hand, Celsion Corporation’s peers have beta of 1.77 which is 76.75% more volatile than Standard and Poor’s 500.
Dividends
Celsion Corporation does not pay a dividend.
Summary
Celsion Corporation’s rivals beat on 3 of the 4 factors Celsion Corporation.
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
